Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | RXRB | P28702 | 2/20 | 0.43 |
| ▸ | RXRG | P48443 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106114 | 0.84 | NPC1 (0.43) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16229042 | 0.84 | NPC1 (0.43) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL104633 | 0.82 | MTNR1A (0.42) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9741507 | 0.81 | RAB9A (0.51) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2438835 | 0.79 | NPC1 (0.50) | POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3600996 | 0.77 | POLB (0.44) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10697865 | 0.76 | HDAC8 (0.47) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10697870 | 0.76 | HDAC8 (0.47) | FFAR1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9366663 | 0.74 | NPC1 (0.48) | POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5250063 | 0.74 | FFAR1 (1.00) | FFAR1FFAR4POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | FFAR1 46/4885FFAR4 192/4885POLB 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.